Request Demo
Novartis floats selling off diagnostic radiopharmaceutical agents: Bloomberg
AcquisitionPhase 3IPOClinical ResultDiagnostic Reagents
Novartis’ Advanced Accelerator Applications division has received diagnostic approvals for Netspot and SomaKit, which label neuroendocrine tumors for imaging scans; Locametz, in prostate cancer; and Gluscan, to help track diseases through glucose metabolism.
Novartis is looking to offload part of its catalog of diagnostic radiopharmaceutical agents, held under its Advanced Accelerneuroendocrine tumorstfolio, according toLocametzt froprostate cancer
Novartisjections pair a radioactive marker with a binder designed to attach to specific proteins that may be overexpressed by certain cancer cells to highlight them for imaging scanners and help outline tumors of the brain, prostate, gastrointestinal system and elsewhere.
Novartis’ AAA division also markets and develops anti-cancer therapies using the same molecular binders—by swapping out a weaker radioactive isotope for a stronger one, it aims to turn precision diagnostic imaging agents into tumor-cell-killing drugs.
Novartisple, the company’s pipeline lists two productscancerrly development targeting a protein found on the surface of cells that help feed blood to growing glioblastoma brain tumors: one employing a gamma-ray-emitting isotoptumorgallium, used in diagnostic PET/CT scans, while the other taps lutetium-177, which emits damaging beta particles.
Lutetium-177 also powers the therapeutic Lutathera—which Novartis recently pitched as a potential first-line therapy in gastroenteropancreatic neuroendocrine glioblastoma brain tumors-NETs, following a successful phase 3 trial last month that combined it with the synthetic hormone Sandostatin.
AAA has also received diagnostic approvalLutatheraspot anNovartist, which use gallium-68 to label neuroendocrine tumors;gastroenteropancreatic neuroendocrine tumorspe in prostate cGEP-NETsnd Gluscan, which helps track glucose metabolism with fluoride-18.Sandostatin
Novartis has been looking to slim down over recent years and has undergone major restructuring whineuroendocrine tumorsutLocametzSandoz generic drug division, slated for prostate cancer year, it also unloaded five eye drugs to ophthalmic company Harrow, and this past summer handed off the dry eye disease eyedrop Xiidra, plus other assets, to Bausch + Lomb in a $2.5 billion deal.
Novartis first acquired AAA, a spinout from CERN launched in 2002, through a $3.9 billion deal in late 2017.SandozHarrowdry eye diseaseBausch + Lomb
RayzeBio’s lead therapeutic candidate uses the same binder as NovartiRayzeBiohera to also target GEP-NETs but swaps out lutetium-177 for actinium-225—an isotope that emits more destructive alpha particles, capable of delivering hundreds of times the energy within a much smaller radius, amounting to just a few widths of a cell.
RayzeBioe, today Eli Lilly announced the acquisition of Point Novartisa Lutathera join the cancer radiopharmaceutical arena for $1.4 billactinium-225—ano lead therapeutic programs are aimed at metastatic castration-resistant prostate cancer and GEP-NETs.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.